CanSino Biologics (Germany) Today
| CJH Stock | EUR 3.98 0.04 1.02% |
Performance12 of 100
| Odds Of DistressLess than 20
|
CanSino Biologics is trading at 3.98 as of the 12th of December 2024. This is a 1.02 percent increase since the beginning of the trading day. The stock's lowest day price was 3.98. CanSino Biologics has about a 20 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat good performance during the last 90 days. The performance scores are derived for the period starting the 16th of May 2024 and ending today, the 12th of December 2024. Click here to learn more.
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the Peoples Republic of China. CanSino Biologics Inc. was founded in 2009 and is headquartered in Tianjin, the Peoples Republic of China. CANSINO BIOLOGICS operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. The company has 114.78 M outstanding shares. More on CanSino Biologics
Moving together with CanSino Stock
Moving against CanSino Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
CanSino Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. CanSino Biologics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding CanSino Biologics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman | Xuefeng Yu |
| Business Concentration | Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
CanSino Biologics (CJH) is traded on Frankfurt Exchange in Germany and employs 1,946 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.15 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate CanSino Biologics's market, we take the total number of its shares issued and multiply it by CanSino Biologics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. CanSino Biologics classifies itself under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 114.78 M outstanding shares.
CanSino Biologics has accumulated about 6.71 B in cash with 2.05 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 27.12, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check CanSino Biologics Probability Of Bankruptcy
Ownership AllocationCanSino Biologics holds a total of 114.78 Million outstanding shares. CanSino Biologics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check CanSino Ownership Details
CanSino Biologics Risk Profiles
Although CanSino Biologics' alpha and beta are two of the key measurements used to evaluate CanSino Biologics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 4.21 | |||
| Semi Deviation | 4.9 | |||
| Standard Deviation | 6.12 | |||
| Variance | 37.45 |
CanSino Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in CanSino Biologics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Price Ceiling Movement Now
Price Ceiling MovementCalculate and plot Price Ceiling Movement for different equity instruments |
| All Next | Launch Module |
CanSino Biologics Corporate Management
Elected by the shareholders, the CanSino Biologics' board of directors comprises two types of representatives: CanSino Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CanSino. The board's role is to monitor CanSino Biologics' management team and ensure that shareholders' interests are well served. CanSino Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CanSino Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Zhu Tao | Chief Scientific Officer, Deputy General Manager, Executive Director | Profile | |
| Yonghui Wu | VP Marketing | Profile | |
| WingYu Leung | Non-Executive Director | Profile | |
| Jianzhong Liu | Independent Non-Executive Director | Profile | |
| FCS FCIS | Joint Sec | Profile | |
| Dongxu Qiu | Senior Vice President Deputy General Manager, Executive Director | Profile | |
| Qiang Xu | Non-Executive Director | Profile |
Other Information on Investing in CanSino Stock
CanSino Biologics financial ratios help investors to determine whether CanSino Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CanSino with respect to the benefits of owning CanSino Biologics security.